These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12409418)

  • 1. Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O.
    Rodés B; Poveda E; Soriano V
    J Clin Microbiol; 2002 Nov; 40(11):4313-6. PubMed ID: 12409418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
    Santos AF; Abecasis AB; Vandamme AM; Camacho RJ; Soares MA
    J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil.
    Tanuri A; Vicente AC; Otsuki K; Ramos CA; Ferreira OC; Schechter M; Janini LM; Pieniazek D; Rayfield MA
    Antimicrob Agents Chemother; 1999 Feb; 43(2):253-8. PubMed ID: 9925514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.
    Gonzalez LMF; Aguiar RS; Afonso A; Brindeiro PA; Arruda MB; Soares MA; Brindeiro RM; Tanuri A
    J Gen Virol; 2006 May; 87(Pt 5):1303-1309. PubMed ID: 16603533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorometric assay for phenotypic differentiation of drug-resistant HIV mutants.
    Zhu Q; Yu Z; Kabashima T; Yin S; Dragusha S; El-Mahdy AF; Ejupi V; Shibata T; Kai M
    Sci Rep; 2015 May; 5():10323. PubMed ID: 25988960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
    Côté HC; Brumme ZL; Harrigan PR
    J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
    Schapiro JM; Winters MA; Lawrence J; Merigan TC
    AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro.
    Merrill DP; Manion DJ; Chou TC; Hirsch MS
    J Infect Dis; 1997 Jul; 176(1):265-8. PubMed ID: 9207379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.
    Holguín A; Paxinos E; Hertogs K; Womac C; Soriano V
    J Clin Virol; 2004 Nov; 31(3):215-20. PubMed ID: 15465415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
    Ntemgwa M; Brenner BG; Oliveira M; Moisi D; Wainberg MA
    Antimicrob Agents Chemother; 2007 Feb; 51(2):604-10. PubMed ID: 17116674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.
    Mammano F; Trouplin V; Zennou V; Clavel F
    J Virol; 2000 Sep; 74(18):8524-31. PubMed ID: 10954553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333.
    Sevin AD; DeGruttola V; Nijhuis M; Schapiro JM; Foulkes AS; Para MF; Boucher CA
    J Infect Dis; 2000 Jul; 182(1):59-67. PubMed ID: 10882582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation.
    Iga M; Matsuda Z; Okayama A; Sugiura W; Hashida S; Morishita K; Nagai Y; Tsubouchi H
    J Virol Methods; 2002 Oct; 106(1):25-37. PubMed ID: 12367727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.
    Rusconi S; La Seta Catamancio S; Citterio P; Kurtagic S; Violin M; Balotta C; Moroni M; Galli M; d'Arminio-Monforte A
    Antimicrob Agents Chemother; 2000 May; 44(5):1328-32. PubMed ID: 10770770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 protease mutations and protease inhibitor cross-resistance.
    Rhee SY; Taylor J; Fessel WJ; Kaufman D; Towner W; Troia P; Ruane P; Hellinger J; Shirvani V; Zolopa A; Shafer RW
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4253-61. PubMed ID: 20660676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
    Desbois D; Roquebert B; Peytavin G; Damond F; Collin G; Bénard A; Campa P; Matheron S; Chêne G; Brun-Vézinet F; Descamps D;
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1545-8. PubMed ID: 18227188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies.
    Race E; Dam E; Obry V; Paulous S; Clavel F
    AIDS; 1999 Oct; 13(15):2061-8. PubMed ID: 10546858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease.
    Martínez MA; Cabana M; Parera M; Gutierrez A; Esté JA; Clotet B
    Antimicrob Agents Chemother; 2000 May; 44(5):1132-9. PubMed ID: 10770741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative SNP-detection method for estimating HIV-1 replicative fitness: application to protease inhibitor-resistant viruses.
    Ibe S; Fujisaki S; Fujisaki S; Morishita T; Kaneda T
    Microbiol Immunol; 2006; 50(10):765-72. PubMed ID: 17053312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
    Turner D; Schapiro JM; Brenner BG; Wainberg MA
    Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.